Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy
Conferences
Ghobadi, A; Baiocchi, R; Beitinjaneh, AM; Chaganti, S; Choquet, S; Dierickx, D; Dinavahi, R; Mahadeo, KM; Mehta, A; Nikiforow, S; Rashef, R ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
September 2025
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
September 2025
Volume
25
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ghobadi, A., Baiocchi, R., Beitinjaneh, A. M., Chaganti, S., Choquet, S., Dierickx, D., … Prockop, S. E. (2025). Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 25).
Ghobadi, Armin, Robert Baiocchi, Amer M. Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, et al. “Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 25, 2025.
Ghobadi A, Baiocchi R, Beitinjaneh AM, Chaganti S, Choquet S, Dierickx D, et al. Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025.
Ghobadi, Armin, et al. “Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 25, 2025.
Ghobadi A, Baiocchi R, Beitinjaneh AM, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Mahadeo KM, Mehta A, Nikiforow S, Rashef R, Roye S, Vedovato J-C, Prockop SE. Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025.
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
September 2025
Volume
25
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology